ReviewAmerican journal of respiratory and critical care medicine2020
Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease.
Open access · hybridAbstract readReview
In one paragraph
Review in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.European respiratory review : an official journal of the European Respiratory Society · 2021Pooled it
- Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.Respiratory research · 2020Pooled it
- Review
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Prognostic Value of the Eosinophil-to-Neutrophil Ratio for In-Hospital Mortality in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Chonnam medical journal · 2026Article
- Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison.Pulmonary therapy · 2026Article
- Characterization of Patients with COPD and GOLD E Classification in the United States.International journal of chronic obstructive pulmonary disease · 2026Article
- Severe COPD Exacerbators Requiring Multiple ICU Admissions Over Time: Insights of a French Cohort.International journal of chronic obstructive pulmonary disease · 2026Article
- COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets.Clinical science (London, England : 1979) · 2025Review
- A translational view of airway epithelial dysfunction in COPD.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Impact of Eosinophil Levels on Disease Progression and Clinical Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Retrospective Study.Medeniyet medical journal · 2025Article
- Diagnosing Type 2 Inflammation in COPD: Comparison of Blood and Sputum Eosinophil Assessment in the University of California Los Angeles COPD Phenotyping Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Artificial neural network risk prediction of COPD exacerbations using urine biomarkers.ERJ open research · 2025Article
- Pharmacogenetic Factors Shaping Treatment Outcomes in Chronic Obstructive Pulmonary Disease.Genes · 2025Review
- Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?American journal of respiratory and critical care medicine · 2025Review
- Decreased Sputum Type-2 Gene Expression in COPD Current Smokers.International journal of chronic obstructive pulmonary disease · 2025Article
- Characteristics and actions in high-risk COPD in unstable patients: The EPOCONSUL audit.PloS one · 2025Article
- Multi-Criteria Decision Analysis of Biologics in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Article
- Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Lack of Association between Inhaled Corticosteroid Use Based on the Exhaled Nitric Oxide and Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Tuberculosis and respiratory diseases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 12 institutions in 4 countries.
Dave SinghDivision of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester University National Health Service Hospital Trust, Manchester, United Kingdom.
Mona BafadhelRespiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-9993-2478
Christopher E BrightlingInstitute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory and Infection Sciences, University of Leicester, Leicester, United Kingdom.
Frank C SciurbaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jeffrey L CurtisPulmonary and Critical Care Medicine, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.ORCID 0000-0001-5191-4847
Fernando J MartinezPulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, New York.
Cara B PasqualeCOPD Patient-Powered Research Network, COPD Foundation, Washington, DC.
Debora D MerrillCOPD Biomarkers Qualification Consortium, COPD Foundation, Miami, Florida.
Norbert MetzdorfBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Stefano PetruzzelliGlobal Clinical Development, Chiesi Farmaceutici, Parma, Italy.
Ruth Tal-SingerCOPD Biomarkers Qualification Consortium, COPD Foundation, Miami, Florida.
Christopher ComptonGlobal Medical Affairs, Speciality and Primary Care, GlaxoSmithKline, Middlesex, United Kingdom.
Stephen RennardBiopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Ubaldo J MartinResearch and Development, AstraZeneca, Gaithersburg, Maryland.
COPD Foundation · USAstraZeneca (United Kingdom) · GBAstraZeneca (United States) · USBoehringer Ingelheim (Germany) · DEChiesi (Italy) · ITCornell University · USGlaxoSmithKline (United Kingdom) · GBNational Health Service · GBUniversity of Leicester · GBUniversity of Michigan · USUniversity of Oxford · GBUniversity of Pittsburgh · US
Funding
Modulation of Steroid Suppression by Alveolar Macrophage EfferocytosisI01CX000911 · VA · VETERANS HEALTH ADMINISTRATION · PI CURTIS, JEFFREY LOUIS · 2016 to 2020
–CSRD VA I01 CX000911
Abstract
PubMed holds no abstract for this paper.
Indexed as
Clinical Trials as TopicEosinophilsHumansLeukocyte CountPulmonary Disease, Chronic Obstructive
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.